Tonghui Ma

2.2k total citations · 1 hit paper
125 papers, 1.4k citations indexed

About

Tonghui Ma is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Tonghui Ma has authored 125 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 45 papers in Pulmonary and Respiratory Medicine and 38 papers in Oncology. Recurrent topics in Tonghui Ma's work include Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (22 papers) and Genetic factors in colorectal cancer (13 papers). Tonghui Ma is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (22 papers) and Genetic factors in colorectal cancer (13 papers). Tonghui Ma collaborates with scholars based in China, United States and Ethiopia. Tonghui Ma's co-authors include Nianyin Lv, Liyun Shi, Youbing Xia, Chunli Zhang, Liangjun Xia, Zihao Liang, Haibo Cheng, Yongming Li, Muhammad Noman Khan and Muhammad Irfan and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Tonghui Ma

111 papers receiving 1.4k citations

Hit Papers

AdMSC-derived exosomes alleviate acute lung injury via tr... 2022 2026 2023 2024 2022 50 100 150 200

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tonghui Ma China 22 679 283 274 247 187 125 1.4k
Huan Deng China 23 692 1.0× 240 0.8× 200 0.7× 321 1.3× 254 1.4× 84 1.7k
Li Liang China 20 554 0.8× 178 0.6× 191 0.7× 389 1.6× 187 1.0× 67 1.3k
Yanfang Zheng China 26 963 1.4× 487 1.7× 177 0.6× 334 1.4× 200 1.1× 102 1.8k
Yang Xu China 24 812 1.2× 449 1.6× 349 1.3× 282 1.1× 166 0.9× 87 1.7k
Huifang Guo China 22 827 1.2× 366 1.3× 226 0.8× 141 0.6× 239 1.3× 65 1.5k
Xiaodong Xie China 19 893 1.3× 231 0.8× 114 0.4× 225 0.9× 162 0.9× 78 1.5k
Atieh Pourbagheri‐Sigaroodi Iran 22 638 0.9× 214 0.8× 158 0.6× 277 1.1× 285 1.5× 59 1.4k
Lijuan Hu China 23 793 1.2× 316 1.1× 97 0.4× 248 1.0× 188 1.0× 112 1.5k

Countries citing papers authored by Tonghui Ma

Since Specialization
Citations

This map shows the geographic impact of Tonghui Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tonghui Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tonghui Ma more than expected).

Fields of papers citing papers by Tonghui Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tonghui Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tonghui Ma. The network helps show where Tonghui Ma may publish in the future.

Co-authorship network of co-authors of Tonghui Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Tonghui Ma. A scholar is included among the top collaborators of Tonghui Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tonghui Ma. Tonghui Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wan, Li, Tonghui Ma, Xiaoming Shi, et al.. (2025). Hypoxia-induced tumor cell-intrinsic PLAU activation drives immunotherapy resistance in collagenic lung adenocarcinoma. International Immunopharmacology. 162. 115161–115161. 1 indexed citations
2.
Ma, Tonghui, Jianguo Zhao, Chenlong Wang, et al.. (2025). HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4–ERK1/2–U2AF2–TFRC axis. Molecular Cancer. 24(1). 241–241.
3.
4.
Liu, Wei, Xiaojuan Wang, Chunyang Wang, et al.. (2024). Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for ImmunoTherapy of Cancer. 12(3). e008450–e008450. 9 indexed citations
5.
Liu, Wenjie, Steven H. Lin, Qin Zhang, et al.. (2024). Bortezomib induces cell apoptosis and increases the efficacy of αPD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1. International Immunopharmacology. 143(Pt 2). 113311–113311. 1 indexed citations
6.
7.
Zhao, Ximeng, Xiang Zhang, Hongling Yuan, et al.. (2023). Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late‐onset cancers. Cancer Medicine. 12(17). 18394–18404. 2 indexed citations
8.
Sun, Xiaojuan, et al.. (2023). Radix Astragali decoction improves liver regeneration by upregulating hepatic expression of aquaporin-9. Phytomedicine. 122. 155166–155166. 9 indexed citations
9.
Ong, Wee Loon, David Joseph, Allison Steigler, et al.. (2023). Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR). International Journal of Radiation Oncology*Biology*Physics. 117(2). S93–S94. 1 indexed citations
10.
Zhou, Shengyu, Lei Zhang, Chunyang Wang, et al.. (2023). Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study. Molecular Oncology. 17(10). 2200–2212. 6 indexed citations
11.
Zhang, Chenghai, Min Shi, Bowen Zhu, et al.. (2023). Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study. Journal of Medical Genetics. 60(8). 760–768. 5 indexed citations
12.
Zhu, Dandan, Na Li, Xuewei Yang, et al.. (2023). AQP4 Aggravates Cognitive Impairment in Sepsis‐Associated Encephalopathy through Inhibiting Na v 1.6‐Mediated Astrocyte Autophagy. Advanced Science. 10(14). e2205862–e2205862. 26 indexed citations
13.
Wang, Li, Yurong Cheng, Jing Yang, et al.. (2022). Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient. Frontiers in Immunology. 12. 784861–784861. 6 indexed citations
14.
Tian, Panwen, Xiaoyan Zhang, Sheng Yang, et al.. (2022). Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients. Journal of genetics and genomics. 49(7). 645–653. 3 indexed citations
15.
16.
Zhang, Chi, Jianwen Wang, Yu Li, et al.. (2020). Dual role of Ca2+-activated Cl− channel transmembrane member 16A in lipopolysaccharide-induced intestinal epithelial barrier dysfunction in vitro. Cell Death and Disease. 11(5). 404–404. 16 indexed citations
17.
Yang, Hong, et al.. (2020). 1963P A pan-cancer study of GNAQ/GNA11 mutations in Chinese cancer patients. Annals of Oncology. 31. S1104–S1105. 2 indexed citations
18.
Ma, Tonghui & Jian Zhang. (2019). Upregulation of FOXP4 in breast cancer promotes migration and invasion through facilitating EMT. SHILAP Revista de lepidopterología. 1 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026